logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12741013 B1

PDFFull Text
Date of Patent:
Sep. 22, 2026

Filed:

Dec. 15, 2025

Pharmaceutical formulations

Applicant:

Novo Nordisk A/s, Bagsvaerd, DK;

Inventors:

Tommy Sander, Smoerum, DK;

Christian Poulsen, Ballerup, DK;

Rosa Rebecca Erritzoee Hansen, Koebenhavn OE, DK;

Assignee:

Novo Nordisk A/S, Bagsvaerd, DK;

Attorney:

Jianjie Hu

Primary Examiner:

Rei Tsang Shiao

Int. Cl.
CPC ...
A61K 38/26 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/4172 (2006.01); A61K 38/17 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/18 (2017.01); A61K 47/22 (2006.01); A61K 47/24 (2006.01); A61K 47/26 (2006.01); A61M 5/19 (2006.01);
U.S. Cl.
CPC ...
A61K 38/26 (2013.01); A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 31/4172 (2013.01); A61K 38/1703 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/183 (2013.01); A61K 47/22 (2013.01); A61K 47/24 (2013.01); A61K 47/26 (2013.01); A61M 5/19 (2013.01);
Abstract

Disclosed herein are an aqueous pharmaceutical formulation comprising cagrilintide and an aqueous formulation comprising semaglutide. The compositions of these two pharmaceutical formulations allow for their presentation in, and administration using, the dual-chamber medical device disclosed herein. Individuals with diseases, such as diabetes and/or obesity and/or related co-morbidities, may benefit from the co-administration of semaglutide and cagrilintide, and/or of the two liquid pharmaceutical formulations disclosed herein, using the medical device disclosed herein.

Find Patent Forward Citations

Sander, Tommy. (2026). Pharmaceutical formulations (U.S. Patent No. 12741013). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12741013

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…